Perfood’s Post

I am convinced that almost every significant discovery is the result of a courageous break with traditional ways of thinking.

📚 Book Review: Status Quo Thinking is Harming Your Health: A Physician’s Final Plea 📚 Dr. Sarah Hallberg's passing in 2022 was a profound loss to the keto/low carb community. In her book, Status Quo Thinking is Harming Your Health: A Physician’s Final Plea, Dr. Hallberg shares her journey and frustrations with conventional medical care, particularly concerning metabolic disease. Written during her final year with Stage IV lung cancer, the book challenges traditional approaches and advocates for therapeutic carbohydrate restriction. Highlights: - A Caring Clinician: Dr. Hallberg's compassionate, individualized patient care and advocacy for empowerment. - Low Carb Advocate: Her pivotal role in Virta Health's groundbreaking studies on ketogenic diets for diabetes reversal. - Challenging the Status Quo: Dr. Hallberg's belief in the potential of carbohydrate reduction to manage type 2 diabetes and other metabolic disorders. Her book is a call to action for healthcare professionals to reconsider conventional wisdom and explore evidence-based alternatives. 📌 Link to the full book review: https://lnkd.in/gSkCQCNW 📖 Link to purchase Dr. Hallberg's book: https://amzn.to/3yGZZuP #Keto #Diabetes #DiabetesReversal #Diabetes #KetogenicDiet #SarahHallberg #StatusQuo #HarmingYourHealth

🌟 Dive into the Intriguing Intersection of Vascular Health & Endocannabinoids! 🌿💓 September is National Vascular Awareness Month—a crucial time to spotlight the importance of vascular health and the innovative research that could transform care. Did you know that endocannabinoids may hold the key to new treatments? Here’s why: 1️⃣ Vascular Importance: From delivering oxygen to fighting diseases, your blood vessels are vital! But factors like diabetes and smoking can lead to serious conditions. 🚭💉 2️⃣ Endocannabinoid System (ECS) Insight: This complex network involves receptors and neurotransmitters that regulate everything from our mood to our immune response—and yes, even our vascular health! 🧠🛡️ 3️⃣ Research Revelations: Studies suggest that manipulating the ECS could help manage vascular tone, reduce inflammation, and prevent vessel blockage. Imagine medications that harness this power without side effects! 🔬🌱 4️⃣ Future Frontiers: With ongoing research and clinical trials, we're on the brink of potentially groundbreaking therapies. What if lifestyle changes could boost your body’s own cannabinoid levels? 🏋️♂️🥗 Want more details on how this exciting science could be a game-changer for vascular health? Click the link below for the full story! 👇 #VascularHealth #EndocannabinoidResearch #InnovativeTherapies #HealthAwareness

What MTM Vision is Doing: ✅ Alerting the Public... to the threat of vision loss and blindness from diabetes. ✅ Raising Awareness... that the current medical tools that measure, diagnose, and assess Diabetic Retinal Disease (DRD) severity are outdated and inadequate. ✅ Identifying New Ways… to better diagnose and more fully assess DRD severity and emphasizing the need for new treatments to prevent and cure vision loss and blindness. ✅ Catalyzing Cures for DRD… by providing eye samples from human donors for study, conducting detailed analysis of these samples, sharing the data, and undertaking clinical trials to identify new paths for progress. ✅ Pioneering Scientific Breakthroughs… to accelerate the development of next-gen treatments for the hundreds of millions of people worldwide with diabetes to prevent and cure vision loss and blindness. ✅ Bringing Together People and Families with diabetes and scientific experts from all sectors to form a global collaborative with a single purpose: to preserve and restore vision in people with diabetes. #MTMVision #Diabetes #MaryTylerMoore 

Imagine waking up each day with the knowledge that managing your health is a balancing act, a task that requires constant vigilance. For the 537 million people living with diabetes worldwide, this isn’t just a thought experiment—it’s reality. And with Type 2 diabetes alone rising 16% in the past two years, the clinical trial landscape is evolving rapidly. Researchers and sponsors need to navigate a complex, competitive landscape of over 1,200 active diabetes trials. From artificial pancreas systems to regenerative therapies, these studies are exploring new frontiers that could reshape diabetes management and quality of life. This 𝗪𝗼𝗿𝗹𝗱 𝗗𝗶𝗮𝗯𝗲𝘁𝗲𝘀 𝗗𝗮𝘆, let’s recognize the relentless work of researchers pushing the boundaries of what’s possible—and the millions of people hoping for a breakthrough that could mean fewer needles, more freedom, and, ultimately, a cure. This clinical trial intelligence has been brought to you by 𝗧𝗔 𝗦𝗰𝗮𝗻, Anju Software’s clinical intelligence solution. 📊

What MTM Vision is Doing: ✅ Alerting the Public... to the threat of vision loss and blindness from diabetes. ✅ Raising Awareness... that the current medical tools that measure, diagnose, and assess Diabetic Retinal Disease (DRD) severity are outdated and inadequate. ✅ Identifying New Ways… to better diagnose and more fully assess DRD severity and emphasizing the need for new treatments to prevent and cure vision loss and blindness. ✅ Catalyzing Cures for DRD… by providing eye samples from human donors for study, conducting detailed analysis of these samples, sharing the data, and undertaking clinical trials to identify new paths for progress. ✅ Pioneering Scientific Breakthroughs… to accelerate the development of next-gen treatments for the hundreds of millions of people worldwide with diabetes to prevent and cure vision loss and blindness. ✅ Bringing Together People and Families with diabetes and scientific experts from all sectors to form a global collaborative with a single purpose: to preserve and restore vision in people with diabetes. #MTMVision #Diabetes #MaryTylerMoore 

#CBCAwardee Dr. Edward Thorp and fellow Northwestern University have been selected to lead 1 of only 3 research centers nationally as part of a $15 million American Heart Association research initiative into inflammation and heart disease. These awards come at a critical time. Of special interest is the role of inflammation in patients with “heart failure with preserved ejection fraction” -- a condition that accounts for more than half of heart failure in the US. It is estimated that 50% of patients with this condition will die within 5 years. 3 projects led by Dr. Thorp and other Northwestern University professors will investigate this condition and other others associated with inflammation and cardiac health. We look forward to the outcomes. https://lnkd.in/gy3kEtrN #ChicagoBiotech #ChiBiotech #HeartHealth

📊 Excited to share our latest translational research evaluating Beat It - Diabetes Australia's national group exercise program for adults with type 2 diabetes! This 8-week program is delivered both online and in-person across Australia. https://lnkd.in/gtr-x3Uc We interviewed accredited exercise physiologists who deliver Beat It in both formats, gaining valuable insights into implementing hybrid delivery models. Our findings offer practical learnings for policy makers and program providers about what works in real-world settings. This paper adds to our growing body of evidence evaluating the Beat It program. Check out our related publications https://lnkd.in/geZcaiJP and https://lnkd.in/gH9AT6CX examining program outcomes and implementation. Thank you to my fantastic co-authors: Kylie Gwynne Christine Chiu Connie Henson Thomas Laing Jonathon Fermanis Jordan Janszen Leah Scott #TranslationalResearch #ExercisePhysiology #DiabetesResearch #DiabetesAustralia #HybridDelivery.

"🔬👩🔬Interested in news from #diabetes research? Then visit the DZD Symposium on May 9 from 4 p.m. at the Diabetes Congress #DK2024. The symposium, chaired by DZD spokespersons Prof. Martin Hrabě de Angelis and Prof. Michael Roden, will feature presentations on: New mechanisms of #remission in #prediabetes by Arvid Sandforth from Tübingen. Towards a precise diagnosis of #diabetes: Visualizing #heterogeneity in type 2 diabetes #T2D with simple clinical variables by Martin Schön from Düsseldorf. Translational research: Exploring the potential of lifestyle interventions with Dr. Heike Vogel from Potsdam / Rehbrücke. New insights into the mechanisms of action of GIP: GLP-1 co-agonists presented by Prof. Timo Müller from Munich. Participation and information of laypersons and affected persons discussed by Dr. Astrid Glaser, DZD Managing Director. Additionally, the symposium will showcase the diabetes information portal diabinfo.de and the involvement of people with diabetes and interested parties in the DZD Citizens' and Patients' Advisory Board. Don't forget, the Silvia King Prize of the German Diabetes Association (DDG) will be awarded during the event, honoring outstanding scientific work in clinical #diabetology. Mark your calendars and join us for an insightful discussion and exchange of ideas at the forefront of diabetes research! #DiabetesResearch #TranslationalResearch #DK2024der #DDG #DZD #Medicine #Healthcare Deutsche Diabetes Gesellschaft (DDG)

During the last couple of days Embla's unique research has been displayed at the European Congress on Obesity (ECO) 2024 in Venice, and described on a number of global media platforms. The Mirror: https://lnkd.in/dhVE3C_S The Standard: https://lnkd.in/dxtyB7ua Perspective Media: https://lnkd.in/d3BAJAqV Our results show that patients can achieve approximately 15% weight loss when our digital service is combined with the use of semaglutide. The weight loss was achieved using only around one third of the usually applied semaglutide dose and that this is achievable regardless of patients initial BMI and the amount of semaglutide used. Moreover, our results show that continuous support through our digital platform (including support from mentors, nurses and physicians) enables tapering of semaglutide while maintaining the achieved weight loss. Henrik Rindel Gudbergsen Kine Stamp-Larsen Jesper Søndergaard Pedersen European Association for the Study of Obesity (EASO)